Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial The Lancet Haematology - Tập 8 Số 3 - Trang e175-e184 - 2021
Tiziano Barbui, Alessandro M. Vannucchi, Valerio De Stefano, Arianna Masciulli, Alessandra Carobbio, Alberto Ferrari, Arianna Ghirardi, Elena Rossi, Fabio Ciceri, Massimiliano Bonifacio, Alessandra Iurlo, Francesca Palandri, Giulia Benevolo, Fabrizio Pane, Alessandra Ricco, Giuseppe Carli, Marianna Caramella, Davide Rapezzi, Caterina Musolino, Sergio Siragusa, Elisa Rumi, Andrea Patriarca, Nicola Cascavilla, Barbara Mora, Emma Cacciola, Carmela Mannarelli, Giuseppe Gaetano Loscocco, Paola Guglielmelli, Silvia Betti, Francesca Lunghi, Luigi Scaffidi, Cristina Bucelli, Nicola Vianelli, Marta Bellini, Maria Chiara Finazzi, Gianni Tognoni, Alessandro Rambaldi
Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study The Lancet Haematology - Tập 7 Số 8 - Trang e575-e582 - 2020
George Goshua, Alexander B. Pine, Matthew L. Meizlish, C‐Hong Chang, Hanming Zhang, Parveen Bahel, Audrey Baluha, Noffar Bar, Robert Bona, Adrienne J. Burns, Charles S. Dela Cruz, Anne Dumont, Stephanie Halene, John Hwa, Jonathan L. Koff, Hope Menninger, Natalia Neparidze, Christina Price, Jonathan Siner, Christopher A. Tormey, Henry M. Rinder, Hyung J. Chun, Alfred Ian Lee
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial The Lancet Haematology - Tập 5 - Trang e73-e81 - 2018
Claire N Harrison, Alessandro M Vannucchi, Uwe Platzbecker, Francisco Cervantes, Vikas Gupta, David Lavie, Francesco Passamonti, Elliott F Winton, Hua Dong, Jun Kawashima, Julia D Maltzman, Jean-Jacques Kiladjian, Srdan Verstovsek
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study The Lancet Haematology - Tập 4 - Trang e475-e486 - 2017
Anna Maria Fink, Jasmin Bahlo, Sandra Robrecht, Othman Al-Sawaf, Ali Aldaoud, Holger Hebart, Kathleen Jentsch-Ullrich, Steffen Dörfel, Kirsten Fischer, Clemens-Martin Wendtner, Thomas Nösslinger, Paolo Ghia, Francesc Bosch, Arnon P Kater, Hartmut Döhner, Michael Kneba, Karl-Anton Kreuzer, Eugen Tausch, Stephan Stilgenbauer, Matthias Ritgen
Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations The Lancet Haematology - Tập 6 - Trang e366-e374 - 2019
Jacob D Soumerai, Ai Ni, Mohamed Darif, Anil Londhe, Guan Xing, Yong Mun, Neil E Kay, Tait D Shanafelt, Kari G Rabe, John C Byrd, Asher A Chanan-Khan, Richard R Furman, Peter Hillmen, Jeffrey Jones, John F Seymour, Jeffrey P Sharman, Lucille Ferrante, Mehrdad Mobasher, Thomas Stark, Vijay Reddy
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial The Lancet Haematology - Tập 8 - Trang e879-e890 - 2021
Jacob D Soumerai, Anthony R Mato, Ahmet Dogan, Venkatraman E Seshan, Erel Joffe, Kelsey Flaherty, Jason Carter, Ephraim Hochberg, Jeffrey A Barnes, Audrey M Hamilton, Jeremy S Abramson, Connie L Batlevi, Matthew J Matasar, Ariela Noy, Colette N Owens, M Lia Palomba, Anita Kumar, Tak Takvorian, Ai Ni, Morgan Choma
Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial The Lancet Haematology - Tập 3 Số 9 - Trang e415-e425 - 2016
A Abdallah, Carl Yan, Raghad Al-Badri, Ella Robinson, Brooke E Kirkby, Emily Ingram, Zara Gray, V. Khelgi, Iain Robertson, Brian Kirkby
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial The Lancet Haematology - Tập 7 - Trang e660-e670 - 2020
Catherine S Diefenbach, Fangxin Hong, Richard F Ambinder, Jonathon B Cohen, Michael J Robertson, Kevin A David, Ranjana H Advani, Timothy S Fenske, Stefan K Barta, Neil D Palmisiano, Jakub Svoboda, David S Morgan, Reem Karmali, Elad Sharon, Howard Streicher, Brad S Kahl, Stephen M Ansell
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial The Lancet Haematology - Tập 7 Số 5 - Trang e370-e380 - 2020
María‐Victoria Mateos, Hareth Nahi, Wojciech Legieć, Sebastian Grosicki, Vladimir Vorobyev, Ivan Špıčka, Vânia Hungria, Sibirina Korenkova, Nizar J. Bahlis, Max Flogegård, Joan Bladé, Philippe Moreau, Martin Kaiser, Shinsuke Iida, Jacob P. Laubach, Hila Magen, Michèle Cavo, Cyrille Hulin, Darrell White, Valerio De Stefano, Pamela L. Clemens, Tara Masterson, Kristen Lantz, Lisa O’Rourke, Christoph Heuck, Xiang Qin, Dolly A. Parasrampuria, Zhilong Yuan, Xu Steven Xu, Ming Qi, Saad Z. Usmani
